n
new
tool
avail
aid
vaccin
manufactur
meet
challeng
new
vaccin
develop
mani
technolog
alreadi
avail
continu
improv
includ
adjuv
novel
vaccin
deliveri
platform
new
method
yet
fulli
exploit
includ
revers
engin
go
pathogen
gene
sequenc
immunogen
epitop
screen
peptid
librari
method
increas
antigen
puriti
crossprotect
thermost
n
persist
highli
variabl
andor
novel
pathogen
complex
eg
polymicrobi
infect
present
challeng
vaccin
design
target
includ
new
prophylact
vaccin
prevent
emerg
diseas
new
therapeut
vaccin
augment
redirect
exist
immun
respons
control
persist
infect
malign
autoimmun
diseas
addict
n
stateoftheart
technolog
combin
comprehens
understand
diseas
aetiolog
pathogen
biolog
host
immun
assist
futur
vaccin
develop
combat
elus
pathogen
protect
popul
special
need
elsevi
bv
advanc
made
vaccin
technolog
sinc
edward
jenner
vaccin
young
jame
phipp
smallpox
spectacular
impact
human
health
last
two
centuri
see
chapter
e
vaccin
evolut
vaccin
fundament
control
elimin
mani
debilit
lethal
diseas
diseas
current
target
erad
vaccin
recent
major
breakthrough
immunolog
molecular
biolog
genom
proteom
biochemistri
comput
scienc
driven
vaccin
technolog
forward
continu
mani
challeng
remain
howev
includ
persist
latent
infect
pathogen
complex
life
cycl
antigen
drift
shift
pathogen
subject
select
pressur
challeng
popul
emerg
infect
address
challeng
research
explor
mani
avenu
novel
adjuv
develop
enhanc
immun
respons
elicit
vaccin
maintain
high
level
toler
method
protect
antigen
identif
iter
everi
success
vaccin
storag
transport
system
improv
includ
optimis
cold
chain
develop
temperaturest
vaccin
new
potenti
conveni
method
vaccin
administr
pursu
high
prioriti
target
includ
lifethreaten
diseas
malaria
tuberculosi
tb
human
immunodefici
viru
hiv
well
problemat
infect
caus
ubiquit
agent
respiratori
syncyti
viru
rsv
cytomegaloviru
cmv
staphylococcu
aureu
nontradit
vaccin
also
like
becom
avail
manag
addict
prevent
treatment
cure
malign
chapter
meant
compendium
newgener
vaccin
rather
outlin
modern
principl
like
facilit
develop
futur
vaccin
shown
figur
sever
key
element
like
understand
modern
vaccin
foundat
develop
futur
vaccin
chapter
illustr
element
provid
exampl
show
promis
sinc
first
use
adjuv
human
vaccin
year
ago
adjuv
technolog
improv
significantli
respect
improv
vaccin
immunogen
efficaci
advanc
adjuv
design
driven
parallel
advanc
vaccin
technolog
mani
modern
vaccin
consist
highli
purifi
antigen
e
low
nonspecif
reactogen
requir
combin
adjuv
enhanc
immun
respons
futur
develop
adjuv
technolog
expect
provid
stronger
immun
prime
enhanc
immun
respons
specif
popul
lead
antigen
spare
adjuv
date
demonstr
abil
new
adjuv
must
aim
drive
immun
respons
associ
lifelong
protect
new
adjuv
adjuv
combin
play
mani
role
futur
vaccin
illustr
figur
adjuv
need
individu
select
specif
vaccin
target
order
achiev
desir
goal
ie
enhanc
immunogen
induct
specif
immun
profil
etc
deliv
aim
adjuv
mix
free
antigen
other
need
coval
link
antigen
moieti
part
complex
molecul
exampl
new
adjuv
evalu
human
clinic
trial
list
tabl
also
see
chapter
e
vaccin
adjuv
modern
approach
antigen
design
tend
eschew
classic
trial
error
techniqu
favour
identifi
type
pathogen
structur
ie
antigen
like
import
immunogen
base
structur
signatur
physic
locat
within
pathogen
tabl
see
chapter
e
vaccin
antigen
b
cell
immun
respons
antigen
target
precis
region
antigen
ie
epitop
e
either
linear
threedimension
conform
structur
case
protein
antigen
specif
peptid
epitop
histor
simpl
linear
synthet
peptid
epitop
vaccin
poorli
immunogen
lack
specif
conform
easili
degrad
varieti
extracellular
cellsurfac
proteas
serv
limit
epitop
present
cell
andor
result
destruct
bcell
epitop
peptid
vaccin
need
union
everi
effort
made
verifi
inform
tabl
inform
includ
meant
exhaust
intend
provid
overview
subject
matter
subunit
individu
epitop
vaccin
need
optimis
ensur
adequ
immunogen
novel
strategi
develop
exploit
order
identifi
antigen
recognis
b
cell
thu
facilit
knowledgebas
vaccin
design
one
common
way
identifi
antigen
measur
cellular
prolifer
b
cell
upon
vitro
stimul
antigen
highthroughput
screen
assay
candid
synthet
peptid
drive
cellular
prolifer
help
speed
rate
antigen
discoveri
revers
vaccinolog
combin
knowledg
pathogen
genom
sequenc
known
protein
sequenc
via
comput
analysi
predict
protein
express
posttransl
modif
identifi
like
vaccin
candid
see
chapter
e
vaccin
antigen
figur
develop
epitopebas
vaccin
one
exampl
revers
vaccinolog
comput
softwar
combin
predict
algorithm
suggest
sequenc
similar
pathogen
compon
epitop
map
combin
creation
stabl
polyepitop
vaccin
may
lead
success
translat
technolog
product
mhc
molecul
exhibit
wide
vari
bind
specif
vaccin
express
singl
peptid
antigen
would
therefor
target
mhc
molecul
thu
recognis
cell
individu
carri
specif
mhc
phenotyp
polyepitop
technolog
could
use
gener
synthet
protein
carri
antigen
epitop
multipl
strain
pathogen
would
overcom
mhc
restrict
afford
protect
individu
carri
differ
mhc
type
screen
pathogen
peptid
librari
anoth
exampl
new
approach
antigen
discoveri
screen
method
use
identifi
antigen
stimul
cell
bind
antibodi
human
known
infect
relev
pathogen
peptid
screen
use
antibodi
addit
consider
synthesi
antigen
contain
tertiari
foldingthreedimension
structur
nativ
immunogen
sinc
vaccin
efficaci
impact
infidel
structur
final
product
incorrect
protein
fold
may
result
less
immunogen
antigen
antigen
induc
immun
respons
differ
nativ
immunogen
mimick
threedimension
structur
nativ
immunogen
import
synthesi
antigen
use
target
bcell
respons
convers
requir
fold
reduc
cell
sinc
cell
bind
process
peptid
degrad
protein
likewis
dna
express
librari
use
pathogen
genom
dna
screen
use
anim
model
system
identifi
gene
encod
protein
afford
protect
infect
diseas
caus
pathogen
one
exampl
genocea
vaccin
develop
programm
built
around
broad
platform
rapid
discoveri
tcell
antigen
process
explain
figur
tcell
antigen
specif
antigen
stimul
cell
critic
gener
diseasespecif
cellular
immun
respons
longterm
tcell
memori
stabil
final
product
anoth
import
consider
advers
environment
condit
result
degrad
vaccin
render
nonimmunogen
order
maintain
product
integr
mani
vaccin
particularli
live
vaccin
must
store
cold
temperatur
c
mainten
vaccin
temperatur
product
site
distribut
site
medic
offic
clinic
refer
cold
chain
maintain
cold
chain
much
less
challeng
resourcerich
countri
major
barrier
vaccin
implement
resourcelimit
area
ongo
research
design
increas
understand
vaccin
degrad
may
address
problem
associ
cold
chain
manag
lead
develop
thermost
vaccin
level
antigen
present
occur
current
vaccin
may
sometim
insuffici
drive
longlast
immun
respons
high
qualiti
see
chapter
e
vaccin
antigen
may
due
inadequ
exposur
antigen
immatur
antigenpres
cell
apc
rapid
subimmunogen
degrad
sequestr
antigen
lack
immunogen
due
physic
present
antigen
discoveri
modifi
vaccin
formul
increas
toler
temperatur
fluctuat
like
increas
shelflif
product
reduc
transport
wastag
issu
understand
modern
vaccin
refin
new
vari
option
antigen
present
expect
allow
design
vaccin
produc
specif
immun
profil
technolog
shown
facilit
oral
deliveri
target
mucos
immun
respons
also
trigger
innat
adapt
immun
system
includ
tand
bcell
effector
memori
respons
candid
viral
vector
vaccin
utilis
nonpathogen
viru
carri
subsequ
induc
express
gene
produc
immunogen
foreign
protein
high
level
host
taken
immatur
apc
shown
lead
robust
longlast
immun
respons
target
antigen
figur
viral
vector
vaccin
eg
recombin
poxviru
vaccin
administ
mucos
stimul
mucos
immun
respons
attenu
modifi
vaccinia
viru
ankara
rmva
vector
show
promis
mucos
deliveri
vector
preexist
immun
viral
vaccin
vector
impedi
success
use
approach
way
avoid
antivector
immun
virus
attenu
inactiv
delet
replac
pathogen
gene
figur
demonstr
viral
vaccin
vector
made
dna
express
immunogen
transgen
vaccin
antigen
insert
viral
vector
genom
express
follow
administr
recipi
express
vaccin
antigen
boost
use
varieti
dna
promot
viral
vector
longer
abl
grow
replic
viru
grown
use
cell
line
socal
complement
cell
line
engin
produc
miss
viral
product
often
viral
gene
remov
effort
reduc
elimin
pathogen
vector
case
viral
gene
remov
make
vector
less
immunogen
antivector
immun
respons
would
greatli
reduc
abil
vector
induc
antigenspecif
respons
exampl
viral
vector
candid
vaccin
clinic
develop
list
tabl
nonpathogen
bacteri
vector
mani
featur
make
attract
vaccin
platform
bacteri
vector
engin
maximum
safeti
eg
delet
two
gene
metabol
pathway
express
larg
number
foreign
antigen
figur
two
key
issu
affect
bacteri
vaccin
vector
decid
whether
optim
platform
bacteri
vaccin
figur
viral
vector
vaccin
viral
vector
vaccin
exploit
natur
abil
virus
infect
otherwis
enter
case
disabl
viral
vector
host
cell
deliv
pathogenspecif
antigen
antigenencod
gene
isol
pathogen
insert
viral
vector
genom
viral
vector
use
factori
product
larg
quantiti
pathogen
antigen
vivo
follow
introduct
vector
vaccin
recipi
pathogen
antigen
express
surfac
infectedtransduc
host
cell
export
produc
cell
mhc
major
histocompat
complex
right
bacteri
vector
system
deliv
exogen
antigen
b
determin
whether
readministr
vector
either
differ
target
antigen
fail
immun
respons
bacteri
vector
vaccin
time
initi
administr
initi
assess
feasibl
use
attenu
bacteri
vector
deliveri
foreign
antigen
focus
salmonella
speci
bacteri
vaccin
vector
human
howev
disappoint
far
may
necessari
develop
uniqu
bacteri
vaccin
vector
deliv
exogen
antigen
case
vector
modifi
allow
reus
exampl
immun
vector
major
impedi
vaccin
reus
determin
antibodi
surfac
structur
bacterium
lipopolysaccharid
lp
dedic
vaccin
vector
could
develop
lack
express
lp
express
truncat
differ
form
lp
target
therebi
avoid
prime
immun
respons
allow
reus
vector
andor
vaccin
potenti
option
live
attenu
bacteri
vector
shown
tabl
dna
vaccin
result
discoveri
earli
gene
rather
encod
protein
deliv
express
form
could
induc
immun
respons
see
chapter
e
vaccin
evolut
principl
behind
dna
vaccin
antigen
molecul
produc
within
host
dna
rna
inject
contrast
tradit
vaccin
antigen
suppli
vaccin
formul
gene
target
antigen
isar
usual
encod
circular
plasmid
express
vector
control
promot
sequenc
direct
gene
express
mammalian
cell
achiev
inject
mammal
dna
vaccin
process
circumv
major
issu
result
recombin
protein
administr
construct
product
plasmid
carri
gene
interest
togeth
promot
sequenc
rel
simpl
antigen
express
plasmid
retain
nativ
conform
gene
readili
modifi
produc
tailor
antigen
bacteri
plasmid
dna
intrins
immunogen
subsequ
shown
result
pathogenassoci
molecular
pattern
pamp
carri
addit
desir
featur
includ
abil
engin
deliv
genet
adjuv
tandem
parallel
antigen
potenti
deliv
multipl
antigen
gene
one
construct
within
construct
encod
adjuv
protein
abil
induc
cellular
humor
immun
respons
despit
promis
data
preclin
test
dna
vaccin
candid
shown
limit
success
clinic
set
far
one
current
drawback
dna
vaccin
ineffici
convent
deliveri
method
plasmid
dna
howev
understand
modern
vaccin
emerg
proprietari
particlemedi
deliveri
technolog
electropor
technolog
seek
improv
situat
electropor
method
brief
electr
puls
appli
site
immunis
caus
transient
disrupt
cell
membran
result
enhanc
uptak
dna
vaccin
exampl
dna
candid
vaccin
clinic
develop
present
tabl
dendrit
cell
dc
vaccin
typic
use
monocyt
harvest
blood
case
individu
receiv
vaccin
produc
immatur
dc
vitro
monocyt
antigenload
treat
induc
matur
apc
infus
back
patient
first
food
drug
administr
fda
approv
dc
vaccin
design
treatment
prostat
cancer
licens
sipuleucelt
exampl
target
dc
vaccin
therapi
present
tabl
dc
vaccin
offer
individualis
approach
therapeut
vaccin
develop
repres
specialis
method
vaccin
current
limit
aggress
cancer
treatment
seriou
intract
infect
comparison
strength
weak
select
new
vaccin
platform
present
tabl
develop
administr
techniqu
place
vaccin
directli
site
pathogen
like
initi
infect
eg
mucos
respiratori
site
like
improv
vaccin
efficaci
safeti
tradit
method
vaccin
administr
potenti
pose
number
limit
respect
reactogen
immunogen
conveni
efficaci
safeti
costeffect
inform
includ
meant
exhaust
intend
provid
overview
subject
matter
ongo
research
altern
experiment
administr
strategi
includ
ballist
deliveri
skin
gene
gun
transderm
patch
intraderm
method
plu
sublingu
aerosol
rectal
vagin
mucos
vaccin
main
advantag
altern
deliveri
strategi
potenti
induc
immun
respons
common
portal
pathogen
entri
eg
oral
polio
vaccin
replic
gut
potenti
conveni
eg
eas
use
transderm
patch
potenti
combin
vaccin
reduc
simplifi
vaccin
schedul
reduct
elimin
administr
via
standard
hypoderm
needl
inject
despit
intuit
valu
approach
vaccin
today
administ
via
nonim
rout
sever
reason
includ
feasibl
lack
proven
efficaci
limit
safeti
data
problem
observ
new
rout
deliveri
exampl
launch
inactiv
intranas
influenza
vaccin
virosom
formul
adjuv
heat
labil
enterotoxoid
escherichia
coli
postlicensur
data
indic
significantli
increas
risk
bell
palsi
vaccine
forc
withdraw
market
experi
led
higher
level
caution
develop
intranas
vaccin
today
exampl
licens
vaccin
latent
infect
zoster
vaccin
vaccin
formul
high
potenc
version
live
attenu
varicella
zoster
viru
vzv
vaccin
vaccin
use
boost
antivzv
cellmedi
immun
respons
older
subject
shown
reduc
overal
incid
zoster
subject
age
year
older
oxman
et
al
futur
vaccin
may
control
persist
infect
either
prevent
initi
infect
diseas
ie
prophylact
vaccin
aerosol
deliveri
mass
immun
almost
suscept
children
short
period
time
potenti
rapidli
elimin
measl
public
health
problem
immun
inhal
aerosolis
measl
vaccin
provid
procedur
could
make
mass
programm
possibl
especi
part
world
measl
continu
seriou
problem
sabin
et
al
administ
measl
vaccin
aerosol
either
nebulis
vaccin
increas
understand
human
immunolog
hostepathogen
interact
enabl
identif
type
immun
requir
effect
prevent
control
persist
infect
see
chapter
e
vaccin
immunolog
exampl
persist
infect
shown
tabl
mycobacterium
tuberculosi
persist
latent
state
within
human
host
year
without
caus
diseas
latent
tb
protect
miliari
dissemin
tb
children
provid
bacil
bcg
vaccin
develop
cultur
attenu
mycobacterium
bovi
earli
centuri
routin
given
mani
countri
vaccin
howev
provid
modest
often
temporari
protect
pulmonari
tb
provid
lower
efficaci
resourcelimit
region
closer
equat
addit
vaccin
live
attenu
mycobacterium
bovi
particular
concern
hivposit
individu
especi
advanc
immun
suppress
popul
would
particularli
benefit
tb
vaccin
tb
lead
caus
death
worldwid
peopl
hivacquir
immunodefici
syndrom
aid
howev
recent
phase
iii
trial
demonstr
protect
tb
provid
individu
hiv
use
inactiv
wholecel
mycobacteri
vaccin
von
reyn
et
al
current
state
tb
vaccin
develop
summaris
review
walker
et
al
lambert
et
al
exampl
vaccin
develop
shown
tabl
cytomegaloviru
herp
viru
establish
latent
infect
cell
bone
marrow
peripher
blood
primari
infect
pregnanc
associ
congenit
infect
frequent
caus
wellcharacteris
spectrum
abnorm
disabl
may
sever
fatal
reactiv
pregnanc
common
unlik
caus
sever
congenit
infect
although
manifest
especi
hear
loss
remain
common
reactiv
cmv
special
concern
immunocompromis
individu
sever
fatal
pulmonari
hepat
central
nervou
system
infect
common
gastrointestin
diseas
retin
common
associ
hiv
success
cmv
vaccin
prove
elus
year
base
upon
observ
antibodi
cmv
envelop
glycoprotein
b
gb
could
pass
et
al
recent
phase
ii
clinic
trial
cmvseroneg
women
year
postpartum
shown
potenti
decreas
incid
case
matern
congenit
cmv
infect
pass
et
al
first
evid
cmv
vaccin
protect
infect
altern
approach
develop
cmv
vaccin
utilis
dna
vaccin
induc
host
respons
cmv
gb
phosphoprotein
anoth
viral
target
recent
studi
shown
inject
combin
plasmid
formul
adjuv
induc
vaccinespecif
immun
respons
prime
effect
memori
respons
hallmark
herp
simplex
viru
type
abil
establish
maintain
latent
infect
exhaust
intend
provid
overview
subject
matter
sensori
ganglion
neuron
period
reactiv
latent
infect
result
recurr
infect
caus
myriad
diseas
greatest
public
health
problem
genit
herp
genit
infect
increas
risk
hiv
acquisit
transmiss
control
genit
herp
predict
significantli
impact
hiv
epidem
given
complex
natur
histori
hsv
infect
vaccin
could
varieti
possibl
risk
benefit
tabl
effect
hsv
vaccin
sought
year
recent
glycoprotein
candid
vaccin
contain
adjuv
see
chapter
e
vaccin
adjuv
test
three
larg
doubleblind
phase
iii
control
trial
first
two
studi
recruit
volunt
partner
genit
herp
diseas
found
candid
vaccin
effect
genit
herp
diseas
women
seroneg
stanberri
et
al
trend
toward
protect
infect
also
observ
statist
signific
candid
vaccin
effect
seroposit
women
understand
modern
vaccin
men
regardless
hsv
seroposit
statu
first
studi
report
signific
differ
vaccin
efficaci
men
women
find
could
import
implic
vaccin
target
sexual
transmit
diseas
basi
differ
could
relat
differ
men
women
respond
novel
adjuv
may
reflect
differ
acquisit
natur
histori
genit
herp
men
women
third
phase
iii
efficaci
trial
candid
vaccin
neg
women
thought
possibl
risk
acquir
genit
herp
differ
risk
popul
origin
two
trial
complet
analys
initi
assess
result
third
trial
show
vaccin
accept
safeti
profil
primari
trial
endpoint
prevent
genit
herp
diseas
met
niaid
although
develop
vaccin
stop
analys
comparison
trial
may
guid
research
continu
seek
vaccin
control
hsv
infect
discuss
chapter
e
vaccin
immunolog
pathogen
complex
life
cycl
one
specif
exampl
parasit
sometim
use
singl
host
develop
phase
mark
differenti
express
major
protein
mean
possibl
antigen
target
hostand
developmentphas
specif
taenid
worm
asid
vaccin
parasit
extrem
difficult
develop
limit
number
perform
well
laterstag
clinic
trial
protozoan
parasit
plasmodium
falciparum
common
caus
malaria
complex
life
cycl
shown
figur
plasmodium
parasit
genom
encod
protein
present
differ
allel
immunogen
tabl
one
furthest
advanc
new
candid
vaccin
rt
vaccin
target
preerythrocyt
stage
parasit
figur
protect
vaccin
target
phase
need
induc
humor
immun
prevent
parasit
invad
liver
cellmedi
immun
destroy
hepatocyt
becom
infect
face
humor
immun
respons
rt
antigen
produc
saccharomyc
cerevisia
contain
sequenc
p
falciparum
circumsporozoit
protein
link
hepat
b
surfac
antigen
hbsag
chimer
protein
spontan
assembl
mix
polymer
particul
structur
phase
ii
studi
rt
candid
vaccin
induc
strong
neutralis
antibodi
respons
cellmedi
immun
afford
protect
malaria
bejon
et
al
abdulla
et
al
rt
select
proceed
phase
iii
clinic
test
due
higher
efficaci
compar
altern
formul
success
rt
candid
vaccin
could
first
licens
human
vaccin
parasit
malaria
candid
vaccin
develop
shown
appendic
supplementari
tabl
pathogen
may
mutat
recombin
chang
antigen
profil
antigen
drift
refer
gradual
process
wherebi
point
mutat
gene
encod
antigen
protein
chang
antigen
suffici
time
previous
effect
antibodi
vaccin
longer
effect
control
pathogen
henc
new
vaccin
need
creat
antigen
shift
dramat
event
recombin
gene
differ
pathogen
strain
give
rise
new
strain
uniqu
antigen
profil
theori
pathogen
suscept
select
pressur
immunolog
environ
provid
strong
select
pressur
provid
bottleneck
drive
select
occur
influenza
virus
high
mutat
frequenc
allow
select
mutant
neutralis
risk
vaccinemedi
immun
select
pathogen
though
certainli
present
difficult
demonstr
moreov
peptid
vaccin
use
antigen
epitop
risk
pathogen
evolut
theoret
increas
howev
phenomenon
regularli
observ
experiment
studi
may
reflect
complex
natur
vaccin
antigen
presenc
immun
respons
multipl
antigen
multipl
epitop
within
antigen
serotyp
replac
distribut
specif
microbi
serotyp
within
commun
chang
introduct
vaccin
occur
bacteri
pathogen
may
consequ
use
capsular
vaccin
address
limit
number
serotyp
similarli
sinc
introduct
use
antibiot
exert
select
pressur
bacteri
strain
lead
select
common
resist
allel
eg
extendedspectrum
betalactamas
esbl
resist
enter
bacteria
betalactamas
resist
gonococci
date
requir
remodel
vaccin
vaccinemedi
immun
escap
howev
new
vaccin
pneumococcu
licens
includ
addit
capsular
type
expand
geograph
coverag
frequent
type
part
counter
observ
phenomenon
serotyp
replac
annual
season
influenza
infect
subject
natur
antigen
drift
requir
reformul
vaccin
drift
occur
evid
deploy
vaccin
acceler
drift
antigen
shift
result
select
pressur
give
rise
viral
strain
contain
mixtur
surfac
antigen
parent
strain
pathogen
undergo
antigen
shift
includ
influenza
virus
figur
present
major
challeng
vaccin
develop
chapter
e
vaccin
adjuv
progress
anoth
approach
problem
influenza
genom
shift
target
weakli
immunogen
conserv
antigen
influenza
protein
one
approach
address
weak
immunogen
antigen
link
potent
tolllik
receptor
adjuv
flagellin
approach
develop
vaxinn
inc
primari
infect
singl
individu
hiv
mutat
surfac
protein
viru
lead
select
cloud
antigen
variant
evad
cellmedi
immun
respons
complic
develop
broadli
effect
vaccin
propens
mutat
given
rise
mani
strain
hiv
figur
two
type
hiv
identifi
common
global
scale
strain
differenti
accord
respect
group
subtyp
clade
within
group
amino
acid
sequenc
viral
envelop
glycoprotein
show
diverg
clade
diverg
within
given
clade
constitut
formid
hurdl
vaccin
develop
made
wors
recombin
clade
produc
circul
recombin
form
crf
differ
antigen
depend
geograph
region
sinc
initi
hiv
vaccin
programm
candid
vaccin
test
phase
iii
clinic
trial
involv
healthi
human
volunt
regrett
attempt
date
fail
yield
licens
hiv
vaccin
question
remain
concern
immun
mechan
behind
vaccin
achiev
partial
protect
regardless
unknown
abil
prevent
infect
least
individu
still
offer
real
hope
global
effect
hiv
vaccin
might
possibl
current
research
compar
immun
respons
subject
natur
protect
hiv
infect
seek
find
elus
immunolog
mechan
protect
help
guid
design
futur
tcell
vaccin
viru
infect
group
streptococc
serotyp
ie
streptococcu
pyogen
account
approxim
case
uncompl
bacteri
pharyng
streptococc
invas
infect
north
america
protein
group
streptococci
major
virul
determin
organ
also
function
major
target
protect
antibodi
one
sever
strategi
vaccin
prevent
infect
base
typespecif
protein
epitop
howev
group
streptococc
vaccin
develop
face
mani
obstacl
widespread
divers
circul
protein
type
ii
immunolog
crossreact
epitop
protein
sever
human
tissu
introduc
autoimmun
risk
iii
anim
model
limit
valu
human
host
group
streptococci
attempt
partial
overcom
obstacl
design
strategi
akin
pneumococc
polysaccharid
vaccin
employ
gener
group
streptococci
multival
proteinbas
vaccin
contain
typespecif
determin
differ
serotyp
multival
vaccin
current
clinic
develop
primeboost
approach
term
prime
boost
heterolog
boost
describ
approach
vaccin
one
type
vaccin
livevector
vaccin
administ
follow
second
type
vaccin
recombin
subunit
vaccin
contrast
tradit
method
homolog
boost
two
dose
vaccin
given
success
intent
primeboost
vaccin
induc
differ
type
immun
respons
enhanc
overal
immun
respons
result
may
occur
one
type
vaccin
given
dose
approach
employ
trial
exampl
tb
cmv
malaria
hiv
candid
vaccin
exampl
studi
new
tb
vaccin
subject
alreadi
prime
live
attenu
bcg
vaccin
boost
subunit
adjuv
vaccin
see
tuberculosi
respiratori
syncyti
viru
common
caus
bronchiol
pneumonia
infant
exacerb
chronic
obstruct
pulmonari
diseas
elderli
develop
effect
vaccin
challeng
natur
immun
rsv
infect
incomplet
reinfect
occur
age
group
moreov
primari
target
popul
vaccin
newborn
young
infant
challeng
popul
rel
immatur
immun
system
presenc
matern
antibodi
may
interfer
vaccin
young
infant
see
chapter
e
vaccin
immunolog
initi
effort
develop
formalininactiv
cell
culturederiv
rsv
vaccin
result
unanticip
enhanc
natur
rsv
diseas
infant
receiv
vaccin
clinic
trial
subsequ
expos
rsv
exacerb
diseas
thought
due
exagger
helper
type
cell
immun
respons
see
chapter
e
vaccin
immunolog
safeti
concern
regard
potenti
vaccin
trigger
prime
immunopatholog
respons
result
cautiou
approach
develop
rsv
vaccin
vaccin
candid
advanc
clinic
develop
use
two
differ
approach
e
one
use
live
attenu
viru
gene
delet
deliber
target
minimis
immunopatholog
respons
approach
use
live
viral
vector
deliv
key
rsv
surfac
antigen
therebi
avoid
risk
immunopatholog
respons
aris
exposur
rsv
viru
infecti
ill
exert
major
burden
diseas
develop
countri
greatest
burden
caus
diseas
current
vaccin
eg
taeniid
cestod
parasit
associ
high
human
morbid
loss
livestock
global
effort
reduc
infect
human
ongo
use
antihelminth
implement
lifestyl
chang
littl
effect
howev
substanti
progress
made
toward
develop
veterinari
vaccin
encourag
investig
potenti
use
similar
vaccin
human
prevent
exampl
hydatid
diseas
aris
infect
echinococcu
granulosu
cysticercosi
infect
taenia
solium
rel
burden
societi
diseas
low
prioriti
fund
unless
comprehens
measur
taken
address
gap
fund
research
global
immunis
coverag
develop
countri
continu
overwhelm
devast
diseas
order
improv
situat
collabor
scheme
underway
bring
togeth
academ
institut
industri
publiccharit
financ
organis
microbiom
project
nation
institut
health
initi
seek
determin
relationship
human
health
chang
human
microbiom
use
revolutionari
sequenc
technolog
characteris
microbiolog
five
bodi
site
e
oral
caviti
skin
vagina
gut
nasal
tractlung
e
associ
may
made
microbiom
associ
either
healthi
bodi
state
diseas
characteris
microb
associ
diseaserel
pathogen
may
allow
develop
new
vaccin
preserv
protect
healthi
microbiom
henc
could
protect
human
health
area
current
research
outlin
box
right
condit
tradit
thought
noninfecti
may
fact
infecti
origin
tabl
therefor
vaccin
could
strategi
prevent
diseas
diseas
may
result
interact
host
genet
background
particular
microb
socal
geneenviron
interact
diseas
establish
link
identifi
infecti
agent
exampl
primari
cmv
infect
known
caus
congenit
mental
retard
similarli
link
bacteri
vaginosi
foetal
prematur
wide
accept
link
establish
other
remain
specul
tabl
candid
vaccin
develop
prevent
treatment
variou
type
addict
basic
concept
induc
product
antibodi
bind
drug
imped
cross
bloodebrain
barrier
exert
psychoact
effect
sever
nicotin
candid
vaccin
enter
clinic
trial
cocain
candid
vaccin
also
shown
benefit
phase
iib
clinic
trial
key
issu
date
nicotin
cocain
candid
vaccin
induc
continu
next
page
high
immunoglobulin
ig
g
antidrug
antibodi
level
appear
critic
achiev
degre
efficaci
candid
vaccin
methamphetamin
addict
also
earli
develop
date
approach
develop
prophylact
cancer
vaccin
target
infecti
diseas
caus
contribut
develop
cancer
hpv
cervic
cancer
hbv
hepatocellular
carcinoma
exampl
infecti
diseas
associ
cancer
shown
tabl
success
develop
nicotin
vaccin
would
expect
reduc
cigarett
smokingrel
lung
cancer
cancer
express
tissuespecif
antigen
target
immun
system
therapeut
cancer
vaccin
aim
target
tumourassoci
antigen
taa
tcell
mediat
immun
respons
taa
relat
genet
chang
drive
cancer
eg
ra
oncogen
inappropri
upregul
express
gene
eg
carcinoembryon
antigen
taa
target
vaccin
aim
maxim
stimul
cytotox
tcell
respons
design
often
includ
adjuv
enhanc
antigen
present
tumour
develop
multistep
process
face
host
immun
respons
frequent
evolv
escap
immun
control
mechan
evas
includ
genet
chang
loss
human
leukocyt
antigentaa
express
induct
immun
regulatori
system
tcell
anergi
due
activ
reg
cell
limit
antitumour
immun
key
approach
therapeut
cancer
vaccin
reset
immun
respons
deliv
antitumour
immun
alter
destroy
cancer
cell
henc
elimin
reduc
tumour
one
strategi
use
patient
tumour
immunogen
therebi
provid
potenti
idiotyp
chang
might
act
taa
conjunct
antigenpres
dc
harvest
patient
activ
vitro
see
dendrit
cell
vaccin
differ
type
therapeut
candid
vaccin
current
undergo
clinic
trial
numer
type
cancer
tabl
advanc
candid
current
phase
iii
describ
chapter
e
vaccin
adjuv
success
develop
therapeut
cancer
vaccin
fda
approv
first
dc
vaccin
oxford
biomedica
mucin
cell
surfac
human
cytokin
asci
antigenspecif
cancer
immunotherapeut
mage
melanomaassoci
antigen
ctl
cytotox
lymphocyt
everi
effort
made
verifi
inform
tabl
inform
includ
meant
exhaust
intend
provid
overview
subject
matter
vaccin
approach
howev
present
opportun
applic
novel
technolog
adjuv
consider
vaccin
design
use
special
popul
includ
immunosenesc
elderli
poor
immunolog
respons
tradit
vaccin
seen
immunocompromis
individu
patient
hiv
transplant
recipi
cross
vaccin
compon
foetal
bloodstream
vaccin
administ
pregnant
women
safeti
immunogen
concern
surround
vaccin
neonat
due
immatur
immun
system
cellmedi
immun
depress
pregnant
women
leav
high
risk
infect
pathogen
includ
harm
foetu
live
attenu
vaccin
contraind
pregnanc
theoret
risk
foetal
infect
vaccin
howev
inactiv
viral
bacteri
vaccin
administ
pregnant
women
therefor
vaccin
infect
includ
sever
pass
mother
foetu
hepat
b
infect
acquir
infant
first
month
life
often
close
contact
mother
latter
case
infant
protect
transfer
matern
antibodi
late
gestat
exampl
diseas
prevent
pregnant
women
includ
influenza
tetanu
diphtheria
probabl
pertussi
diseas
caus
socal
torch
pathogen
toxoplasma
other
includ
syphili
cmv
hsv
yet
prevent
vaccin
though
encourag
phase
ii
result
present
vaccin
prevent
group
b
streptococcu
carriag
pregnant
women
hillier
et
al
smith
pandem
influenza
outbreak
pose
increas
risk
pregnant
women
vaccin
specif
recommend
pregnant
women
one
highrisk
group
pandem
exampl
emphasis
import
protect
pregnant
women
influenza
season
influenza
vaccin
pregnanc
well
toler
benefiterisk
profil
administ
pregnant
women
support
use
pregnanc
mani
public
health
author
worldwid
recommend
season
influenza
vaccin
pregnant
women
recommend
motiv
potenti
sever
cours
influenza
pregnanc
also
need
protect
vulner
infant
influenza
first
month
life
boost
rsv
immun
pregnant
women
vaccin
may
anoth
approach
protect
newborn
rsv
infect
vulner
earli
month
birth
neonat
immunis
strategi
protect
infant
infect
particularli
vulner
period
recent
studi
show
immunis
acellular
pertussi
vaccin
birth
month
age
induc
high
igg
antipertussi
antibodi
titr
month
age
wood
et
al
hope
approach
may
reduc
death
morbid
bordetella
pertussi
infect
first
month
life
elderli
respond
poorli
vaccin
immun
system
becom
senesc
increas
age
therefor
new
vaccin
technolog
need
improv
respons
vaccin
popul
late
influenza
vaccin
adjuv
oilinwat
emuls
shown
effect
induc
high
immun
respons
elderli
minutello
et
al
altern
vaccin
administr
techniqu
also
studi
elderli
research
show
subject
year
age
older
influenza
vaccin
administ
intraderm
microinject
system
induc
significantli
higher
antibodi
titr
compar
im
vaccin
arnou
et
al
subsequ
microinject
system
influenza
vaccin
licens
use
europ
high
antigen
dose
formul
licens
elderli
usa
individu
cancer
hiv
infect
asplen
immunocompromis
result
condit
patient
also
immunocompromis
result
therapi
eg
receiv
organ
transplant
radiat
therapi
immunosuppress
medic
patient
therefor
elev
risk
infect
pathogen
herpesvirus
particularli
cmv
epsteinebarr
viru
hbv
hcv
pneumocysti
coinfect
repres
special
popul
regard
immunis
despit
like
reduct
efficaci
vaccin
immunocompromis
individu
immunis
remain
frequent
recommend
hope
least
partial
immun
achiev
elicit
respons
vaccin
immunocompromis
patient
may
requir
increas
dose
andor
number
dose
alter
dose
interv
select
differ
vaccin
formul
administr
via
altern
rout
evid
patient
popul
lack
guidelin
often
base
theoret
assumpt
live
vaccin
gener
contraind
immunocompromis
immunosuppress
individu
due
risk
activ
symptomat
infect
result
vaccin
noncontrol
replic
process
encouragingli
vaccin
formul
highli
purifi
antigen
novel
adjuv
altern
deliveri
shown
induc
effect
immun
respons
classic
inactiv
vaccin
immunocompromis
host
includ
patient
endstag
renal
diseas
prehaemodialysi
haemodialysi
see
chapter
e
vaccin
adjuv
patient
hiv
receiv
haematolog
stem
cell
transplant
futur
vaccin
develop
build
knowledg
experi
gain
last
year
time
take
advantag
cuttingedg
technolog
understand
modern
vaccin
research
new
approach
antigen
select
product
antigen
deliveri
adjuvant
vaccin
administr
allow
us
target
establish
emerg
diseas
popul
complex
need
vaccin
one
success
costeffect
health
intervent
ever
conceiv
expand
cancer
chronic
diseas
expans
scope
subsequ
impact
human
diseas
like
continu
futur
current
unforeseen
way
increas
import
vaccin
scienc
engin
improv
human
health
